![](https://investorshub.advfn.com/uicon/522650.png?cb=1464431304)
Tuesday, May 29, 2018 10:41:09 AM
Elite Pharmaceuticals, Inc ( ELTP ) announced today the signing of a license, manufacturing, and supply agreement with Glenmark Pharmaceuticals, Inc., USA to market two Elite generic products in the United States with the option to add products in the future.
Interesting. We've discussed Glenmark before. They were the ones who sponsored Lehigh Valley Pharma efforts to get an NDA for oxycodone 5mg capsules via the 505b2 pathway. Small world, eh? (Or maybe not.)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=124579915
Next I started trying to track down the fed Tmax for oxycodone tablets, and it turns out that it is not public information, as far as I can find. But! I did find the fed Tmax for oxycodone capsules! I don’t understand the full history of how this happened, but somehow along the way a bunch of generic manufacturers started making oxycodone 5mg in capsule form and oxycodone solution with a different manufacturing technique. They were doing this without proper approvals and the FDA swept them all off the shelf at once, similar to what they did to us with Lodrane. Lehigh Valley (with Glenmark Pharmaceuticals) subsequently received approval for their two products via 505b2 NDA’s for a 5mg capsule- and a second NDA for oral solution. Both NDA’s use Roxicodone as a reference product.
Call on God but row away from the rocks.
-Hunter S. Thompson
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 08:07:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2024 08:30:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 09:55:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 07:21:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2023 09:20:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 09:20:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/28/2023 12:05:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 11:58:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 11:50:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration with ZenaDrone • InvestorsHub NewsWire • 11/16/2023 12:32:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/25/2023 08:15:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/07/2023 08:05:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 09:30:05 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 07/31/2023 08:20:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/17/2023 08:15:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/29/2023 09:15:09 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/29/2023 08:43:45 PM
FEATURED POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM